药品和治疗

The European Union is strongly committed to ensuring a high level of protection, competitiveness and innovation...

The European Union is strongly committed to ensuring a high level of protection, competitiveness and innovation in the field of public health.
In the context of medicines and treatment, key objectives are to guarantee access to medicines at an affordable cost, ensure that medicines are safe and effective, and improve the quality and dissemination of information to citizens to enable them to make informed choices about their own treatment.
To further efforts in these and other areas, the European Commission has created the Pharmaceutical Forum, a high-level platform for discussion supported by expert working groups who meet regularly to develop recommendations and exchange best practice. The aim is to improve the performance of the pharmaceutical industry in terms of its competitiveness and contribution to social and public health objectives. The EU promotes research, the development of innovative therapies and the free movement of medicines in the internal market. Together with Member States and stakeholders, the EU is developing a strategic research agenda. This will identify critical scientific gaps in which more research is urgently required to ensure improved well-being for all.

The authorisation and surveillance of medicinal products available on the market is a further key area of activity. The EU has established the European Medicines Agency (EMEA) to provide Member States with the best possible scientific advice on questions about the quality, safety and efficacy of medicinal products.

The EU is also making efforts to improve access to essential medicines in developing countries.